These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20608144)

  • 1. Dosimetry doesn't seem to predict the control of organ-confined prostate cancer after I-125 brachytherapy. Evaluation in 150 patients.
    Gastaldi E; Chiono L; Gallo F; Schenone M; Ninotta G; Chiarlone R; Ghiso G; Giberti C
    Arch Ital Urol Androl; 2009 Dec; 81(4):215-7. PubMed ID: 20608144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-response study for I-125 prostate implants.
    Stock RG; Stone NN; Tabert A; Iannuzzi C; DeWyngaert JK
    Int J Radiat Oncol Biol Phys; 1998 Apr; 41(1):101-8. PubMed ID: 9588923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer.
    Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
    Radiother Oncol; 2006 May; 79(2):185-9. PubMed ID: 16701911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer.
    Stone NN; Stock RG; Unger P
    J Urol; 2005 Mar; 173(3):803-7. PubMed ID: 15711273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms.
    Stock RG; Stone NN; Dahlal M; Lo YC
    Brachytherapy; 2002; 1(2):83-9. PubMed ID: 15062175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.
    Shiraishi Y; Yorozu A; Ohashi T; Toya K; Saito S; Nishiyama T; Yagi Y; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1069-75. PubMed ID: 25539368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
    Potters L; Cao Y; Calugaru E; Torre T; Fearn P; Wang XH
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):605-14. PubMed ID: 11395226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization.
    Stock RG; Stone NN; Kao J; Iannuzzi C; Unger P
    Cancer; 2000 Oct; 89(8):1829-34. PubMed ID: 11042580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of prostate volume on dosimetry results in real-time 125I seed implantation.
    McNeely LK; Stone NN; Presser J; Chircus JH; Stock RG
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):292-9. PubMed ID: 14697451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Permanent implant brachytherapy for early, organ-confined prostate cancer].
    Agoston P; Major T; Fröhlich G; Baricza K; Szabó Z; Lövey J; Varjas G; Kásler M; Fodor J; Polgár C
    Magy Onkol; 2011 Sep; 55(3):170-7. PubMed ID: 21918742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
    Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
    Radiother Oncol; 2005 Jun; 75(3):303-6. PubMed ID: 15890423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy.
    Keyes M; Macaulay C; Hayes M; Korbelik J; Morris WJ; Palcic B
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):829-34. PubMed ID: 23688814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
    Papagikos MA; Deguzman AF; Rossi PJ; McCullough DL; Clark PE; Lee WR
    Brachytherapy; 2005; 4(4):252-8. PubMed ID: 16344254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
    Papagikos MA; Rossi PJ; Urbanic JJ; deGuzman AF; McCullough DL; Clark PE; Lee WR
    Am J Clin Oncol; 2007 Apr; 30(2):199-204. PubMed ID: 17414471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.